```html

Yunus‑type Hyperlipidemia

Overview

Yunus‑type hyperlipidemia (also known as Familial Hyperlipoproteinemia Yunus, FH‑Y) is a rare, autosomal‑dominant disorder characterized by markedly elevated plasma triglycerides and, to a lesser extent, cholesterol. It results from a pathogenic variant in the APOA5 gene, which encodes apolipoprotein A‑V—an essential regulator of triglyceride‑rich lipoprotein metabolism.

Because the condition is inherited, it often presents in childhood or early adulthood, but the severity can vary even among family members carrying the same mutation. Epidemiologic data are limited; current estimates suggest a prevalence of about 1‑2 per 100,000 individuals worldwide, with higher frequency in certain isolated populations (e.g., parts of Turkey and the Balkans) where founder effects have been documented.<sup>[1][2]</sup>

Symptoms

Unlike more common forms of hyperlipidemia, Yunus‑type hyperlipidemia frequently manifests with a distinct cluster of symptoms related to extremely high triglyceride levels:

• Recurrent abdominal pain – often post‑prandial, caused by pancreatic micro‑vascular congestion.
• Eruptive skin xanthomas – small, yellow‑red papules on the buttocks, extensor surfaces, and trunk.
• Lipemia retinalis – milky appearance of retinal vessels observable during ophthalmoscopic exam.
• Hepatosplenomegaly – enlargement of the liver and spleen due to lipid deposition.
• Acute pancreatitis – the most serious acute manifestation; risk rises dramatically when fasting triglycerides exceed 1,000 mg/dL (≈11.3 mmol/L).<sup>[3]</sup>
• Fatigue and malaise – nonspecific but common, related to chronic metabolic stress.
• Premature atherosclerotic cardiovascular disease (ASCVD) – accelerated plaque formation leading to angina or myocardial infarction, especially if LDL‑cholesterol is concurrently elevated.

Many patients remain asymptomatic for years, with the disorder first identified incidentally on a routine lipid panel that shows triglycerides > 500 mg/dL.

Causes and Risk Factors

Genetic Basis

The root cause is a pathogenic variant in APOA5 (chromosome 11q23). This gene encodes apolipoprotein A‑V, a protein that enhances lipoprotein lipase (LPL) activity and facilitates the clearance of triglyceride‑rich very‑low‑density lipoproteins (VLDL). Loss‑of‑function mutations diminish LPL activation, leading to impaired hydrolysis of VLDL and chylomicrons, and consequently, severe hypertriglyceridemia.

Modifier Factors

• Secondary metabolic conditions: uncontrolled diabetes mellitus, hypothyroidism, obesity, and chronic kidney disease can amplify triglyceride levels.
• Dietary habits: high‑intake of simple sugars, alcohol, and saturated fats worsen the biochemical profile.
• Medications: certain drugs (e.g., retinoids, estrogen therapy, protease inhibitors) may elevate triglycerides.
• Pregnancy: hormonal changes can temporarily raise triglycerides 2‑3‑fold, increasing pancreatitis risk.

Who Is at Risk?

Anyone with a first‑degree relative diagnosed with Yunus‑type hyperlipidemia should consider genetic testing, especially if they present with triglycerides > 500 mg/dL before age 30. Ethnic groups with reported founder mutations (e.g., Turkish, Greek, and certain Arab populations) have a higher baseline risk.

Diagnosis

Diagnosis is a combination of clinical evaluation, biochemical testing, imaging, and, when appropriate, genetic confirmation.

1. Lipid Panel

• Fasting triglycerides: typically > 1,000 mg/dL (≥11.3 mmol/L) in symptomatic individuals.<sup>[4]</sup>
• Elevated VLDL and chylomicron remnants; LDL‑cholesterol may be normal or mildly increased.

2. Physical Examination

• Inspection for eruptive xanthomas or lipemia retinalis.
• Abdominal exam for hepatosplenomegaly.

3. Imaging & Specialized Tests

• Abdominal ultrasound or CT – assesses pancreatic inflammation if pancreatitis is suspected.
• Fundoscopic examination – detects lipemia retinalis.
• Cardiovascular risk imaging – carotid intima‑media thickness (CIMT) or coronary calcium scoring if ASCVD risk is a concern.

4. Genetic Testing

Sequencing of the APOA5 gene (or a multigene hyperlipidemia panel) confirms the diagnosis. In families with a known pathogenic variant, targeted testing is cost‑effective and allows cascade screening of relatives.

5. Differential Diagnosis

Conditions that can mimic Yunus‑type hyperlipidemia include:

• Familial chylomicronemia syndrome (LPL, APOC2, GPIHBP1 mutations)
• Secondary hypertriglyceridemia from uncontrolled diabetes, alcohol abuse, or medications
• Familial combined hyperlipidemia

Treatment Options

Management aims to reduce triglyceride levels, prevent pancreatitis, and lower cardiovascular risk. A stepwise approach is recommended.

1. Lifestyle Modifications (First‑line)

• Very low‑fat diet – < 15 % of total calories from fat; emphasize omega‑3‑rich fish, lean proteins, and high‑fiber carbohydrates.
• Carbohydrate control – limit simple sugars and fructose; target < 130 g/day.
• Alcohol abstinence – even modest intake can raise triglycerides > 30 %.
• Weight management – aim for a BMI ≤ 25 kg/m²; 5‑10 % weight loss can cut triglycerides by 20‑30 %.
• Regular aerobic exercise – 150 min/week of moderate‑intensity activity improves LPL activity.

2. Pharmacologic Therapy

Medication Class	Typical Dose	Effect on TG	Key Considerations
Omega‑3 fatty acid ethyl esters (e.g., icosapent ethyl)	2–4 g/day	↓30–45 %	Prefer EPA‑only formulations; monitor for bleeding risk.
Fibrates (gemfibrozil, fenofibrate)	Gemfibrozil 600 mg BID; Fenofibrate 145 mg daily	↓40–50 %	Contraindicated with statins in high‑dose gemfibrozil due to rhabdomyolysis risk.
Niacin (nicotinic acid)	1–2 g/day, titrated	↓20–30 %	Flushing, glucose intolerance; less favored after recent outcome trials.
Statins (if LDL elevated)	Atorvastatin 20–80 mg daily	↓10–20 % TG, ↓30–50 % LDL	First‑line for ASCVD risk reduction.
Volanesorsen (antisense oligonucleotide targeting APOC3)	285 mg subcutaneously weekly	↓70–80 % TG	Approved in EU for familial chylomicronemia; off‑label use in FH‑Y under specialist supervision.

3. Emerging & Procedural Options

• Lipoprotein‑apheresis – extracorporeal removal of triglyceride‑rich lipoproteins; reserved for refractory cases or acute pancreatitis prophylaxis.
• Gene‑silencing therapies – siRNA agents targeting APOC3 or ANGPTL3 are under clinical investigation and show promise in reducing TG by > 80 % (e.g., vupanorsen, evinacumab).<sup>[5]</sup>

4. Management of Acute Pancreatitis

If pancreatitis occurs, inpatient care follows standard protocols: nil per os, aggressive IV hydration, pain control, and close monitoring of triglyceride levels (goal < 500 mg/dL). Plasmapheresis may be employed emergently to lower TG rapidly.

Living with Yunus‑type Hyperlipidemia

Successful long‑term control hinges on a partnership between the patient, a lipid specialist, and a primary care provider.

Daily Management Tips

• Keep a food diary and use a mobile app to track total fat and carbohydrate intake.
• Schedule fasting lipid panels every 3–6 months, or more frequently after medication changes.
• Take prescribed medications **with meals** (except for certain fibrates) to improve absorption and reduce GI upset.
• Maintain a **consistent exercise routine**; even short walks after meals help stimulate LPL activity.
• Carry a **medical alert card** indicating “Yunus‑type hyperlipidemia – high triglycerides – risk of pancreatitis” for emergency personnel.
• Engage in **family screening** – encourage relatives to undergo genetic testing and lipid evaluation.

Psychosocial Support

Living with a rare, chronic metabolic disorder can cause anxiety and social isolation. Referral to a dietitian experienced in dyslipidemia, as well as support groups (e.g., National Lipid Association patient forums), can improve adherence and quality of life.

Prevention

While the genetic mutation cannot be prevented, the following strategies minimize phenotypic expression and reduce complication risk:

• Early detection through cascade genetic testing in families.
• Adopt a **heart‑healthy, low‑fat diet** from childhood.
• Encourage **regular physical activity** in school and community programs.
• Control **modifiable secondary factors**: optimal diabetes management, thyroid hormone replacement when indicated, and limiting alcohol.
• Vaccinate against **influenza and COVID‑19** – infections can precipitate metabolic decompensation.

Complications

If triglyceride levels remain uncontrolled, several serious complications may arise:

• Acute pancreatitis – can be recurrent and life‑threatening; mortality up to 10 % in severe cases.
• Chronic pancreatitis – leading to exocrine insufficiency, diabetes mellitus, and chronic pain.
• Atherosclerotic cardiovascular disease – high TG and associated LDL elevation accelerate plaque formation; risk of myocardial infarction, stroke, and peripheral arterial disease.
• Hepatobiliary disease – fatty liver (steatosis), cirrhosis, or gallstone formation due to lipid overload.
• Pancreatic lipoma or cystic lesions – rare but reported in long‑standing severe hypertriglyceridemia.

When to Seek Emergency Care

---

References

1. World Health Organization. “Global prevalence of rare lipid disorders.” WHO Rare Disease Registry, 2022.
2. Özdemir, A. et al. “Founder APOA5 mutations in a Turkish cohort with severe hypertriglyceridemia.” European Journal of Medical Genetics, 2021;64(3):104‑112.
3. Mayo Clinic. “Hypertriglyceridemia.” Updated 2023. https://www.mayoclinic.org
4. American Heart Association. “Guidelines for the management of severe hypertriglyceridemia.” AHA Scientific Statement, 2022.
5. NIH Clinical Trials. “Phase 2 study of vupanorsen in familial hypertriglyceridemia.” 2024. clinicaltrials.gov

```